Find policies, billing codes, payers, states, and providers
CPT 81410: Genomic Sequencing Panel for Aortic Dysfunction
CPT code 81410 denotes a genomic sequencing panel that analyzes at least nine genes linked to aortic dysfunction or dilation. This molecular diagnostic code captures targeted multi-gene testing used to identify heritable thoracic aortic disease and related genetic contributors. Such testing informs clinical evaluation, risk stratification, and family risk assessment, making it clinically significant across specialty care and genetic counseling programs nationwide.
Key payers included in the analysis are Aetna, Blue Cross Blue Shield, Cigna Health, United Healthcare, and Medicare. Readers will find an overview of coverage and billing considerations for CPT code 81410, comparisons to related molecular pathology codes, and clinical context relevant to cardiology, medical genetics, and laboratory services. The publication outlines typical service settings, common use cases, and where CPT code 81410 fits within the spectrum of genomic testing for aortic disease.
The report provides benchmarks for utilization and coding relationships (including related codes such as 81411 and 81479), highlights common procedural scenarios, and summarizes documentation and clinical indications that typically accompany claims for this panel. Data not available in the input are noted where applicable.
Customize your policy alerts
Sign up for cpt 81410 policy alerts
Get alerted when payer policies referencing 81410 are released or updated.
Monitor payer policy activity
Billing Code Overview
CPT code 81410 describes a genomic sequencing panel performed by a laboratory analyst to evaluate a patient specimen for genetic sequences of at least nine genes associated with aortic dysfunction or dilation. The service is a molecular diagnostic genomic sequencing procedure focused on inherited or heritable contributors to thoracic aortic disease.
Service Type: Genomic sequencing panel (molecular pathology / molecular diagnostics)
Typical Site of Service: Clinical laboratory or hospital molecular diagnostics laboratory; specimen collection occurs in outpatient clinics or hospital outpatient settings.
National Reimbursement Benchmarks
Commercial national rates for CPT 81410 cluster around BUCA’s average commercial rate of $523, which serves as a useful cross-payer anchor. Blue Cross Blue Shield shows the highest dispersion between the 75th and 25th percentiles (range $180, from $432 to $624), indicating broader variability in negotiated commercial payments, while Aetna and UnitedHealth Group display narrower interquartile spreads: Aetna’s IQR is $184 (from $229 to $413) and UnitedHealth Group’s IQR is $287 (from $212 to $504). Cigna’s IQR is $379 (from $258 to $656) and BUCA’s IQR is $248 (from $347 to $581).
In absolute terms, Blue Cross Blue Shield and Cigna exhibit the widest variability, suggesting more heterogeneous contracting outcomes across markets. Aetna and BUCA sit closer to the middle of the distribution, and UnitedHealth Group’s statistics reflect a tighter lower quartile but a higher upper quartile, producing an intermediate spread. These differences highlight payer-specific dispersion without implying suitability for any single contract strategy.